Send to:

Choose Destination
See comment in PubMed Commons below
Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1611-36.

The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina.

Author information

  • 1Department of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.


Ischemic heart disease (IHD) is a major cause of death in Western Countries and accounts for very high costs worldwide. In this review we discussed the pathogenesis, symptoms, diagnosis, prognosis and management of chronic IHD. In particular, we discussed about the percutaneous coronary interventions and coronary artery bypass grafting, as well as to clinical trials that evaluated the advantages of one approach versus another. Pharmacological treatment is among major objectives of the review and for each class of therapeutic agents an evaluation of well-conducted clinical trials is provided. The most important drug classes in IHD treatment are betablockers, calcium channel blockers, nitrates, antiplatelet agents, and ACE-inhibitors. In addition to these agents, also new treatment options are evaluated in patients with stable IHD. Ranolazine, in particular, is a innovative anti-anginal drug with a great successful in the management of patients with refractory angina. A pharmacological as well as clinical profile of this drug is provided.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for European Review for Medical and Pharmacological Sciences
    Loading ...
    Write to the Help Desk